JANESVILLE, WI – December 4, 2013 SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes and cancer treatment elements, announced today that the Nuclear Regulatory Commission (NRC) has accepted for review the second half of SHINE’s construction permit application to build a medical isotope production plant near Janesville, WI. The second half of the construction permit application includes the remainder of the preliminary safety analysis report and SHINE’s plans for dealing with potential emergencies, if any, at the facility. The first half of the construction permit application was accepted by the NRC for review on June 25, 2013.
The acceptance of the remainder of the construction permit application is a significant accomplishment. The acceptance review confirms that SHINE has met the regulatory requirements for the application, including providing a preliminary safety assessment and an evaluation of the environmental impacts. The acceptance of the application is a significant milestone for the company and an important step in the development of domestic production of medical isotopes.
With the acceptance review completed, the NRC’s detailed technical review will commence. In the coming weeks, the NRC will publish a review schedule that identifies significant milestones and an expected review completion date. There will be opportunities for public involvement. The NRC may ask for additional information and a hearing will be scheduled to be conducted before the construction permit is approved. Their final approval of the construction permit will allow SHINE to proceed with the construction of the plant. An additional application for an operating license will be prepared by SHINE and approved by the NRC before production operations can start.
Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth. Want to learn more about SHINE? Follow us on social media @shinefusion and sign up for our email newsletter to follow us on our journey!
Media Contact: info@shinefusion.com
